Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

ONTC-534 shows promising activity in prostate cancer models

Oct. 20, 2021

HPK1 inhibitor RGT-197 potentiates antitumor immunity

Oct. 20, 2021

Drosophila model reveals damaging effect of tumors on blood-brain barrier permeability

Oct. 20, 2021

Targeting integrated epigenetic/metabolic pathways lowers EZHIP in a subset of PFA ependymomas

Oct. 20, 2021

NCI awards SBIR grant to Orphagen to develop OR-449 for adrenocortical carcinoma

Oct. 19, 2021

Exo Therapeutics divulges new EED inhibitors

Oct. 19, 2021

Carna Biosciences identifies hSTING antagonists

Oct. 19, 2021

Dong-A ST patents AhR modulators

Oct. 19, 2021

BGS-1989: a promising compound for treating WDR5-dependent cancers

Oct. 19, 2021

Ipsen collaborates with Accent Therapeutics on preclinical METTL3 inhibitor program

Oct. 18, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.